By "Heart-on-a-chip" technology - simulating the human heart on an engineering chip and using microelectrodes to measure the effects of compound exposure, it is possible to ensure that potential life-saving new drugs are safe and effective, while reducing the need for humans and animal testing.

In 2021, the global Heart-on-a-chip market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027.
This report focuses on the global Heart-on-a-chip status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Heart-on-a-chip development in North America, Europe, Japan, China, Southeast Asia, India, etc.

Global Heart-on-a-chip Scope and Market Size
Heart-on-a-chip market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Heart-on-a-chip market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Children Heart-on-a-chip
Adult Heart-on-a-chip

Segment by Application
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Other End Users

By Region
North America
Europe
Japan
China
Southeast Asia
India

By Company
Emulate
Tissuse
Hesperos
CN Bio Innovations
Draper Laboratory
Mimetas
Nortis
Kirkstall
Cherry Biotech SAS
Else Else Kooi Laboratory
Micronit Microtechnologies B.V.
Tara Biosystems